Treatment of Oligometastatic BRAFV600E Mutant Colorectal Cancer: Learning From a Clinical Case

IF 3.2 3区医学 Q2 ONCOLOGY

Clinical colorectal cancer Pub Date : 2025-03-25 DOI:10.1016/j.clcc.2025.03.003

Renato Maria Marsicano , Luca Boscolo Bielo , Elena Guerini Rocco , Mariano Lombardi , Emilio Bertani , Filippo Maria Bassi , Giuseppe Curigliano , Davide Ciardiello , Nicola Fazio , Maria Giulia Zampino

引用次数: 0

Abstract

•
Treatment with Encorafenib plus Cetuximab is one standard option of care in patients with BRAF V600E-mutated (MT) metastatic colorectal cancer (mCRC).
•
Treatment of oligometastatic disease in BRAFV600E MT CRC remains a topic of debate.
•
Here, we present the case of a patient with oligometastatic lymph nodes-only involvement treated with target therapy and loco-regional treatment.

查看原文本刊更多论文

少转移性BRAFV600E突变型结直肠癌的治疗：从一个临床病例的学习。

•对于BRAF v600e突变（MT）转移性结直肠癌（mCRC）患者，恩科非尼加西妥昔单抗治疗是一种标准的治疗选择。•BRAFV600E MT结直肠癌低转移性疾病的治疗仍然是一个有争议的话题。•在这里，我们报告了一例仅涉及少转移淋巴结的患者，接受了靶向治疗和局部区域治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical colorectal cancer 医学-肿瘤学

CiteScore

5.50

自引率

2.90%

发文量

审稿时长

27 days

期刊介绍： Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.